Johnson & Johnson (JNJ) Offering Possible 14.42% Return Over the Next 3 Calendar Days

Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $167.50 short put and a strike $162.50 long put offers a potential 14.42% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $167.50 by expiration. The full premium credit of $0.63 would be kept by the premium seller. The risk of $4.37 would be incurred if the stock dropped below the $162.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 79.32 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

EMA Says Heart Inflammation Likely Linked To mRNA-Based COVID-19 Vaccines
Fri, 09 Jul 2021 18:34:58 +0000
European Medicines Agency (EMA) has established a probable link between heart inflammation and mRNA-based COVID-19 vaccines made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA). The EMA said that heart conditions myocarditis and pericarditis must be listed as possible side effects of the two mRNA vaccines. This included an in-depth review of 145 cases of myocarditis and 138 cases of pericarditis in Europe among people who received BioNTech SE's (NASDAQ: BNTX) Comirnaty and 19 cases in t

Doctor: I would ‘discourage’ getting booster shot different from the vaccine you received
Fri, 09 Jul 2021 18:22:16 +0000
Dr. Adrian Burrowes, Family Medicine Physician &CFP Physicians Group, CEO,  joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

Abbott Lays Off Around 400 Employees As COVID-19 Test Demand Evaporates
Fri, 09 Jul 2021 18:21:08 +0000
View more earnings on PFESee more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative ColitisPfizer, BioNTech Working On COVID-19 Booster Shot Targeting Delta Variant© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

10 Best Dividend Stocks for Long Term
Fri, 09 Jul 2021 17:17:19 +0000
In this article, we will be looking at the 10 best dividend stocks for long term. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Best Dividend Stocks for Long Term. Dividend investing is a strategy that has managed to stick around as long as it has for two […]

Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis
Fri, 09 Jul 2021 16:49:04 +0000
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced new three-year data from the long-term extension (LTE) of the Stelara (ustekinumab) Phase 3 UNIFI study. Investigators designed the trial to evaluate the safety and efficacy of induction and maintenance doses for the treatment in moderate to severely active ulcerative colitis patients. The study enrolled adults who could not tolerate conventional treatments, such as corticosteroids and immunomodulators or biologics.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.